{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:58:28Z","timestamp":1740135508946,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lichenoid drug eruption is rare and can mimic idiopathic lichen planus and other dermatoses. Clonazepam, a commonly used drug for the treatment of anxiety-related disorders and seizures, is known to be an unlikely cause of cutaneous adverse effects. Only one case report of LDE due to clonazepam has been reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 81-year-old male patient with Alzheimer\u2019s disease developed a lichenoid eruption after taking clonazepam. He developed a violaceous scaly patch on his lower extremities, from both buttocks to the feet. The cutaneous eruption resolved 2\u2009months after cessation of clonazepam and with initiation of corticosteroid therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A skin eruption that develops after clonazepam administration can be a lichenoid drug eruption, which is less likely to resolve spontaneously and requires discontinuation of clonazepam administration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03132-2","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T17:02:44Z","timestamp":1614877364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clonazepam-induced lichenoid drug eruption: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Hee Won","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3913-1011","authenticated-orcid":false,"given":"Jong Bin","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Im","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Woong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"issue":"1","key":"3132_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00281-015-0540-2","volume":"38","author":"W Hoetzenecker","year":"2016","unstructured":"Hoetzenecker W, Nageli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016;38(1):75\u201386.","journal-title":"Semin Immunopathol"},{"issue":"2 Pt 1","key":"3132_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0190-9622(93)70176-T","volume":"29","author":"S Halevy","year":"1993","unstructured":"Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol. 1993;29(2 Pt 1):249\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"3132_CR3","volume-title":"Klonopin tablets (clonazepam) Klonopin wafers (clonazepam orally disintegrating tablets)","author":"US FDA","year":"2010","unstructured":"US FDA. Klonopin tablets (clonazepam) Klonopin wafers (clonazepam orally disintegrating tablets) 2010. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/017533s046s048,020813s006s007lbl.pdf."},{"issue":"2","key":"3132_CR4","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1111\/jdv.13862","volume":"31","author":"K Muramatsu","year":"2017","unstructured":"Muramatsu K, Ujiie H, Natsuga K, Nishie W, Shimizu H. Lichenoid drug eruption caused by clonazepam. J Eur Acad Dermatol Venereol. 2017;31(2):e117\u2013e8.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"3132_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF00868807","volume":"242","author":"P Scheltens","year":"1995","unstructured":"Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995;242(9):557\u201360.","journal-title":"J Neurol"},{"issue":"2","key":"3132_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351\u20136.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"3132_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"3132_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/HRP.0000000000000227","volume":"27","author":"V Dokkedal-Silva","year":"2019","unstructured":"Dokkedal-Silva V, Berro LF, Galduroz JCF, Tufik S, Andersen ML. Clonazepam: indications, side effects, and potential for nonmedical use. Harv Rev Psychiatry. 2019;27(5):279\u201389.","journal-title":"Harv Rev Psychiatry"},{"issue":"5","key":"3132_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1046\/j.1365-2230.1998.00358.x","volume":"23","author":"B Amichai","year":"1998","unstructured":"Amichai B, Grunwald MH. Erythema multiforme due to clonazepam - supportive evidence from the macrophage migration inhibition factor test. Clin Exp Dermatol. 1998;23(5):206\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"2 Pt 1","key":"3132_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0190-9622(96)80143-5","volume":"34","author":"KB Gordon","year":"1996","unstructured":"Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Domer P, et al. Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. J Am Acad Dermatol. 1996;34(2 Pt 1):304\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3132_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1089\/cap.2011.0059","volume":"22","author":"RN Munoli","year":"2012","unstructured":"Munoli RN, Praharaj SK, Bhatt SM. Localized exfoliating rash with paresthesia possibly due to clonazepam. J Child Adolesc Psychopharmacol. 2012;22(4):320\u20131.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"3132_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/WNF.0b013e31816932a6","volume":"32","author":"O Virit","year":"2009","unstructured":"Virit O, Savas HA. Hair loss associated with clonazepam. Clin Neuropharmacol. 2009;32(1):56.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"3132_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1177\/0091270011423923","volume":"52","author":"MC Lee","year":"2012","unstructured":"Lee MC, Su CP, Wang CH, Lan CC, Wu TW. Suspected clonazepam-induced bullous dermatosis in a patient with respiratory failure. J Clin Pharmacol. 2012;52(10):1607\u20139.","journal-title":"J Clin Pharmacol"},{"key":"3132_CR14","doi-asserted-by":"crossref","unstructured":"Yoshida A, Sugita K, Tani N, OY. Correlation between serum TARC levels and eczematous drug eruption following oral challenge test with clonazepam. Clin Exp Dermatol. 2020;45(8):1063-5.","DOI":"10.1111\/ced.14293"},{"key":"3132_CR15","first-page":"24","volume":"86","author":"S Pourshahidi","year":"2020","unstructured":"Pourshahidi S, Samami M. Clonazepam-induced Oral Lichenoid reaction: a case report. New York State Dent J. 2020;86:24\u20137.","journal-title":"New York State Dent J"},{"issue":"3","key":"3132_CR16","first-page":"e7155","volume":"12","author":"P Forouzan","year":"2020","unstructured":"Forouzan P, Riahi RR, Cohen PR. Atorvastatin-induced Lichenoid drug eruption: a case report and review of statin-associated cutaneous adverse events. Cureus. 2020;12(3):e7155.","journal-title":"Cureus."},{"issue":"5","key":"3132_CR17","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1046\/j.1468-3083.2003.00810.x","volume":"17","author":"VR Ruiz","year":"2003","unstructured":"Ruiz VR, Blasco MJ, Linares SJ, Serrano OS. Lichen planus-like eruption due to enalapril. J Eur Acad Dermatol Venereol. 2003;17(5):612\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3132_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0190-9622(95)90155-8","volume":"32","author":"SV Roten","year":"1995","unstructured":"Roten SV, Mainetti C, Donath R, Saurat JH. Enalapril-induced lichen planus-like eruption. J Am Acad Dermatol. 1995;32:293\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"3132_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000247209","volume":"187","author":"A Kanswar","year":"1995","unstructured":"Kanswar A, Dhar S, Ghosh S. Photosensitive lichenoid eruption due to enalapril. Dermatology. 1995;187:80.","journal-title":"Dermatology."},{"issue":"2","key":"3132_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3132_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/archinte.162.4.405","volume":"162","author":"DA Flockhart","year":"2002","unstructured":"Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162(4):405\u201312.","journal-title":"Arch Intern Med"},{"issue":"3","key":"3132_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.18176\/jiaci.0225","volume":"28","author":"A Agullo-Garcia","year":"2018","unstructured":"Agullo-Garcia A, Garces Sotillos M, Colas SC. Fixed drug eruption due to Lorazepam. J Investig Allergol Clin Immunol. 2018;28(3):185\u20136.","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03132-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-021-03132-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03132-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T17:08:08Z","timestamp":1614877688000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03132-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3132"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03132-2","relation":{},"ISSN":["1471-244X"],"issn-type":[{"type":"electronic","value":"1471-244X"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"7 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We obtained ethical approval from the Institutional Review Board of the Seoul National University Bundang Hospital (IRB No. L-2020-598-3).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written consent from the patient was obtained for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}